Premium
Thymoquinone Ameliorates Tamoxifen Induced Hepatotoxicity and Augments its Anti‐cancer Activity in Breast Cancer
Author(s) -
Koladia Mohit,
Kaur Jasmine,
Tikoo Kulbhushan
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.785.14
Subject(s) - thymoquinone , tamoxifen , medicine , cancer , breast cancer , pharmacology , mammary tumor , liver cancer , in vivo , cancer research , chemistry , antioxidant , biology , biochemistry , microbiology and biotechnology
Hepatotoxicity accounts for the limited use of Tamoxifen (TAM) for breast cancer. Herein we investigated if Thymoquinone (TQ) can abate TAM induced toxicity. Our data suggests that TQ co‐treatment prevented the extensive weight loss in TAM treated female SD rats with DMBA induced mammary tumors. Moreover, TQ effectively lowered the levels of sGOT and sGPT which were elevated by TAM treatment. Similarly, TQ elevated the levels of anti‐oxidant enzymes GSH, SOD and CAT which was lowered in TAM treated animals. Also, the protein expression of iNOS, NF‐kB and TNF‐α was found to be lower in the liver of combination treated animals. In addition we also investigated the chemo‐synergizing effect of TQ in breast cancer cells and in vivo mammary cancer model. Our studies revealed that the treatment of cells with TAM (10 μM) in combination with TQ (25 μM) augmented the cell death. Also, TQ potentiated the antitumor activity of TAM in rats with mammary tumors, as was depicted by reduced tumor volumes in combination treated group. Henceforth we report, for the first time, that TQ apart from lowering TAM associated hepatotoxicity also potentiates the anti‐cancer activity of TAM.